Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 20/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2722788 | 0.83 | KCNJ1 (0.58) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL2734302 | 0.81 | KCNJ1 (0.53) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL22606865 | 0.77 | KCNJ1 (0.64) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL2734299 | 0.76 | KCNJ1 (0.51) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL15964291 | 0.76 | KCNJ1 (0.61) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL299891 | 0.76 | KCNJ1 (0.48) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL29195571 | 0.76 | KCNJ1 (0.63) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL15437662 | 0.74 | KCNJ1 (0.61) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL20168319 | 0.74 | KCNJ1 (0.64) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL20166827 | 0.74 | KCNJ1 (0.62) | KCNJ1KCNH2ACHESSTR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3087077-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2018-10-31 | — | — | EP | disclosed |
| US-9073882-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-07-07 | — | — | US | disclosed |
| US-8673920-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2427444-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 16/4885ACHE 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.